Published in Gene Therapy Weekly, November 9th, 1998
The process covered by the patent enables large numbers of antigen-specific T cells (CD4+ or CD8+ T lymphocytes) to be produced from an initially very small number of such cells. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.